All News

hand stopping falling dominos

Can we prevent psoriatic arthritis?

d Antoni Chan, MD, PhD

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.

Read Article
RA,polyarticular,black,rheumatoid

EULAR 2024: New drugs for RA?

d Aurelie Najm, MD, PhD

Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.

Read Article
Telemedicine

AI meets Rheumatology: ChatGPT and patient response optimization

d Bella Mehta, MBBS, MS

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.

Read Article
OP0018 @RheumNow #EULAR2024 🔎 Study looked at early RA patient trajectories through time-independent disease state 📊 Authors demonstrated 4⃣ trajectories in early RA 🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
➡️ OP0064 @RheumNow #EULAR2024 ➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment ➡️ NAP, esp regional NAP, common in early RA during 1st yr ➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.

Mrinalini Dey DrMiniDey ( View Tweet)

TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 @RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
200 millions pts PSO 1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi 2nd line ttmt, IL12-23i 32% & IL-23i 31% IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs Can't exclude some channeling bias, but that's a big signal! @RheumNow OP0010 #EULAR2024 #EULARBest

Aurelie Najm AurelieRheumo ( View Tweet)

AMPLIFIED RCT, 300+ pts ABA NOT (!) superior to ADA in dual seropositive SE+ MTX IR RA pts ACR50 rate high in both gps ABA 59% vs ADA 64% No new safety signal Defeating the encouraging data from smaller trials Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.

Dr. John Cush RheumNow ( View Tweet)

What is the origin of pain in difficult to manage axSpA? 1- Inflammation 2- Degenerative 3- Central Nervous System #EULAR2024 NZ https://t.co/KzATnYN4HG

Links:

Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Ph III RCT SHR0302 JAK1 selective inhibitor in RA 500+ pts ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40% ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7% Safety similar other JAKi Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.

Bella Mehta bella_mehta ( View Tweet)

Great 1st #EULAR2024 scientific session: “Asymptomatic” Hyperuricemia — innocent bystander vs. menacing foe. Data re: effects on joints, kidneys, & heart have not supported clear clinical consequences w/ exception of kidney crystal deposition. TIGER Study results eagerly awaited. https://t.co/IPQU3Ww0NA

Links:

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope. Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️ @RheumNow https://t.co/rwFtYRlpLY

Links:

David Liew drdavidliew ( View Tweet)
#EULAR204 Encouraging Timeline for future potential treatments for #SLE #Lupus @LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6

Links:

TheDaoIndex KDAO2011 ( View Tweet)
What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×